申请人:Japan Tobacco Inc.
公开号:EP1162196A1
公开(公告)日:2001-12-12
The present invention provides a fused ring compound of the following formula [I]
wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hapatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.
本发明提供了下式[I]的融合环化合物
其中各符号如说明书中所定义,其药学上可接受的盐,以及含有该化合物的丙型肝炎治疗剂。本发明的化合物具有基于 HCV 聚合酶抑制活性的抗丙型肝炎病毒(HCV)作用,可用作丙型肝炎的治疗剂或预防剂。